Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

AK, Kakkar; MN, Levine; Z, Kadziola; NR, Lemoine; V, Low; HK, Patel; G, Rustin; M, Thomas; M, Quigley; RC, Williamson

doi:10.1200/jco.2004.10.002

Public

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

Shared by NobleBlocks on May 1, 2004 • 12:00 AM UTC

Authors:

Kakkar AK

Levine MN

Kadziola Z

Abstract

Purpose In experimental systems, interference with coagulation can affect tumor biology. Furthermore, it has been suggested that low molecular weight heparin therapy may prolong survival in patients with cancer. The primary aim of this study was to assess survival at 1 year of patients with advanced...

Discussions